Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 肝络通咀嚼片治疗慢性乙型肝炎肝硬化门静脉高压症随机、双盲、安慰剂平行对照的多中心Ⅱa期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase IIa clinical trial of Ganluotong chewable tablets in the treatment of portal hypertension in patients with chronic hepatitis B cirrhosis
探索肝络通咀嚼片治疗慢性乙型肝炎肝硬化门静脉高压症患者的给药剂量与疗程,初步评价肝络通咀嚼片的有效性和安全性。
[Translation] To explore the dosage and course of Ganluotong chewable tablets in the treatment of portal hypertension in patients with chronic hepatitis B cirrhosis, and to preliminarily evaluate the efficacy and safety of Ganluotong chewable tablets.
100 Clinical Results associated with Beijing Huaxin Wanbang Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Beijing Huaxin Wanbang Pharmaceutical Technology Co., Ltd.
100 Deals associated with Beijing Huaxin Wanbang Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Beijing Huaxin Wanbang Pharmaceutical Technology Co., Ltd.